
The Wall Street Journal @WSJ
A government rule limiting access to Alzheimer’s drugs means most patients who would want newly approved Leqembi won’t be able to get it—unless the Medicare agency rewrites the rule https://t.co/0SKAm3R08h — PolitiTweet.org